NextWave Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NextWave Pharmaceuticals, Inc.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.
In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.